Marker Therapeutics (MRKR) Income from Discontinued Operations (2022 - 2023)
Marker Therapeutics (MRKR) posted quarterly Income from Discontinued Operations of 2179657.0 for Q2 2023, up 45.66% year-over-year from 1496360.09 in Q2 2022, and down 193.46% quarter-over-quarter from 742751.0 in Q1 2023.
Marker Therapeutics (MRKR) Income from Discontinued Operations (2022 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Income from Discontinued Operations for 2 consecutive years, with 2179657.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Income from Discontinued Operations rose 45.66% year-over-year to 2179657.0; the TTM figure through Dec 2023 stood at 2922408.0 (changed N/A YoY), while the FY2023 annual figure was 2922406.0, up 71.22% from the prior year.
- Income from Discontinued Operations eased to 2179657.0 in Q2 2023 per MRKR's latest filing, from 742751.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 742751.0 in Q1 2023 and bottomed at 4011437.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -742,751.00 |
| Dec 31, 2022 | -813,062.00 |
| Sep 30, 2022 | -1.19 Mn |
| Jun 30, 2022 | -4.01 Mn |